Innovative Cancer Detection PetDx's flagship product, OncoK9, offers a first-in-class multi-cancer early detection blood test for dogs, providing a unique selling point for veterinary clinics seeking advanced diagnostic tools to improve pet health outcomes.

Strategic Partnerships The company's collaboration with Petco enhances its market reach by integrating canine cancer screening services in popular retail pet clinics, opening opportunities for sales expansion through established veterinary and pet retail networks.

Strong Funding Backing With $62 million in Series B funding and recent leadership appointments, PetDx is positioned for growth, enabling sales teams to target veterinary practices and clinics eager to adopt innovative biotech solutions supported by solid financial backing.

Rapid Market Entry Since launching OncoK9 in June 2021, PetDx has begun scaling adoption across U.S. pet clinics, offering an attractive opportunity for sales professionals to engage early adopters in the veterinary diagnostics segment.

Technological Edge Utilizing advanced genomic analysis, next-generation sequencing, and proprietary bioinformatics, PetDx provides sophisticated diagnostic technology that can appeal to high-end veterinary practices focused on cutting-edge pet healthcare solutions.